2-(1H-benzimidazol-1-yl)-N-(4-(tertbutyl)phenyl)acetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-(1H-benzimidazol-1-yl)-N-(4-(tertbutyl)phenyl)acetamide
• 英文别名: 2-(1H-Benzimidazol-1-yl)-N-(4-tert-butylphenyl)acetamide；2-(benzimidazol-1-yl)-N-(4-tert-butylphenyl)acetamide
• 化学式: C₁₉H₂₁N₃O
• 分子量: 307.395
• InChiKey: WWAXQKIDOWUEMV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  46.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  苯并咪唑 在 苄基三乙基氯化铵 、 potassium carbonate 、 N,N'-羰基二咪唑 、 potassium hydroxide 作用下， 以 水 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 72.5h， 生成 2-(1H-benzimidazol-1-yl)-N-(4-(tertbutyl)phenyl)acetamide
  参考文献：
  名称：

  ANALGESIC AND ANTI-INFLAMMATORY ACTIVITY OF NEW ANALOGUES OF HC-030031: A TRPA1 CHANNEL ANTAGONIST

  摘要：

  One of our study direction is research in the group of compounds affecting the TRPA1 ion channel (Transient receptor potential cation channel, subfamily A, member 1) which can perform an important function in pain (including neuropathic pain) and inflammation for example in asthma and other chronic respiratory diseases. The aim of this study was to evaluate the analgesic and anti-inflammatory activity of two analogs of HC-030031 analogs belonging to nitrogen derivatives of the heterocyclic system: xanthine (compound 1) and benzimidazole (compound 2) with hydrazide and amide moieties respectively. In this paper, for two derivatives (compound 1 and compound 2) potential analgesic and anti-inflammatory/anti-edematous activities were evaluated in animal models of pain in mice (writhing response test, formalin test) and inflammation in rats (carrageenan-induced paw edema test). Both the tested compounds 1 and 2 showed significant analgesic and anti-inflammatory activities.

  DOI：

  10.32383/appdr/117836

文献信息

• New benzimidazole derivatives
  申请人：Besidski Yevgeni

  公开号：US20060287377A1

  公开（公告）日：2006-12-21

  Compounds of formula I, wherein R 1 , m, R 2 , R 3 , p, n, R 5 and R 9 are as defined as in the specification, salts, solvates or solvated salts thereof, processes for their preparation, intermediates used in the preparation thereof, pharmaceutical formulations containing said compounds and the use of said compounds in therapy.

  公式I的化合物，其中R1、m、R2、R3、p、n、R5和R9的定义如规范中所述，其盐、溶剂合物或溶剂化盐，其制备过程，用于制备中间体，含有上述化合物的制药配方以及在治疗中使用上述化合物。
• Benzimidazole derivatives
  申请人：AstraZeneca AB

  公开号：US07645784B2

  公开（公告）日：2010-01-12

  Compounds of formula I, wherein R1, m, R2, R3, p, n, R5 and R9 are as defined as in the specification, salts, solvates or solvated salts thereof, processes for their preparation, intermediates used in the preparation thereof, pharmaceutical formulations containing said compounds and the use of said compounds in therapy.

  本发明涉及公式I的化合物，其中R1、m、R2、R3、p、n、R5和R9如规范中所定义，以及其盐、溶剂合物或溶剂化盐，其制备方法、制备中所使用的中间体、含有所述化合物的制药配方以及所述化合物在治疗中的应用。
• Benzimidazole derivatives as vanilloid receptor antagonists
  申请人：AstraZeneca AB

  公开号：EP2042490A2

  公开（公告）日：2009-04-01

  The present invention relates to new compounds of formula I, wherein R1 to R9 are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.

  本发明涉及式 I 的新化合物、 其中 R1 至 R9 如式 I 所定义，或其盐类、溶解物或溶解盐，其制备工艺和用于制备的新中间体，含有上述化合物的药物制剂，以及上述化合物在治疗中的应用。
• NEW BENZIMIDAZOLE DERIVATIVES
  申请人：AstraZeneca AB

  公开号：EP1626964B1

  公开（公告）日：2009-01-21
• US7645784B2
  申请人：——

  公开号：US7645784B2

  公开（公告）日：2010-01-12